Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews (original ) (raw )Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
Clive Kelly , Anita Patel
BMJ (Clinical research ed.), 2015
View PDFchevron_right
Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice
Markku J Kauppi
Rheumatology, 2017
View PDFchevron_right
The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference
Rosario Foti
Rheumatology (Oxford, England), 2018
View PDFchevron_right
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
Christopher McCabe
Health technology assessment (Winchester, England), 2018
View PDFchevron_right
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Taylor Blachley
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials
Joachim Listing
Arthritis & Rheumatism, 2006
View PDFchevron_right
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis
Hasan Yazici
Clinical and experimental rheumatology
View PDFchevron_right
Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis
Zsombor Zrubka
Advances in Therapy, 2019
View PDFchevron_right
Cost-effectiveness of combination disease-modifying antirheumatics vs. tumour necrosis factor inhibitors in active rheumatoid arthritis: TACIT trial
Fowzia Ibrahim
Arthritis Care & Research
View PDFchevron_right
Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists
Lesley-Ann Miller
Joint Bone Spine, 2006
View PDFchevron_right
The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy
Paul Emery
Rheumatology (Oxford, England), 2004
View PDFchevron_right
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
Ana Rodrigues
Rheumatology, 2012
View PDFchevron_right
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
Rashid Kazerooni , Anthony Morreale
PharmacoEconomics, 2012
View PDFchevron_right
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Alberto Alonso
BMC Musculoskeletal Disorders, 2008
View PDFchevron_right
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis
Alfons Den Broeder
Annals of the Rheumatic Diseases, 2003
View PDFchevron_right
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Sae Ochi
Arthritis Research & Therapy
View PDFchevron_right
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry
Joel Kremer
Annals of the rheumatic diseases, 2014
View PDFchevron_right
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
Catherine Reynolds
BMC musculoskeletal disorders, 2014
View PDFchevron_right
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Olalekan Uthman
Health Technol Assess, 2011
View PDFchevron_right
Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
Ted Mikuls
Current rheumatology reports, 2003
View PDFchevron_right
Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland
Markku J Kauppi
Scandinavian Journal of Rheumatology, 2016
View PDFchevron_right
Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?
md mainuddin
Modern Rheumatology
View PDFchevron_right
Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up
Ahmed Fathy
International Journal of Rheumatic Diseases, 2012
View PDFchevron_right
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor
Maria Sole Chimenti
Journal of International Medical Research, 2016
View PDFchevron_right
Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
Gavin Lee
Clinical Rheumatology, 2011
View PDFchevron_right
Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder
Ronan Mullan
Arthritis Research & Therapy, 2013
View PDFchevron_right
anti-TNF agent? (TNF) agents after previous failure of an versus alternative anti-tumour necrosis factor arthritis benefits from switching to rituximab Which subgroup of patients with rheumatoid
Anca I Ciurea
2010
View PDFchevron_right
Impact of Stopping Tumor Necrosis Factor-inhibitors on Rheumatoid Arthritis Patients' Burden of Disease
LINA WIDYA
Arthritis care & research, 2017
View PDFchevron_right
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Delphine Courvoisier , Axel Finckh
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?
Fowzia Ibrahim
Rheumatology
View PDFchevron_right
Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database
Rachelle Buchbinder
Rheumatology, 2011
View PDFchevron_right
Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis
Mariangela Manfredi , Maurizio Benucci
International journal of immunopathology and pharmacology
View PDFchevron_right